Company intelligence / Profile preview

Veravas

Charleston, South Carolina, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Veravas is a laboratory diagnostic company focused on sample transformation for precise biomarker detection. Its core proprietary platform, VeraBIND, uses magnetic nanoparticles to isolate biomarkers from complex samples (blood, urine, saliva, stool), enabling more sensitive assay detection. Veravas has launched VeraBIND Tau, the first blood-based test for tau pathology in Alzheimer's disease, aiming to deliver higher accuracy and earlier diagnosis. The VeraBIND platform is also being developed for saliva-based Alzheimer’s detection and future applications in Parkinson’s and cancer diagnostics.

Therapeutic areas: Neurology
Modalities: DeviceNanoparticle
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Veravas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Veravas.

Explore the full profile